BioNTech SE (NASDAQ:BNTX) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its stake in BioNTech SE (NASDAQ:BNTX) by 4.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,295,817 shares of the company’s stock after selling 220,701 shares during the period. Primecap Management Co. CA’s holdings in BioNTech were worth $489,508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the period. Quintet Private Bank Europe S.A. increased its position in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the period. GAMMA Investing LLC increased its position in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares during the period. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech in the fourth quarter worth $137,000. Finally, AlphaCentric Advisors LLC acquired a new stake in BioNTech in the fourth quarter worth $168,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Performance

BNTX opened at $100.86 on Tuesday. The stock has a market cap of $24.18 billion, a PE ratio of -48.03 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The stock’s 50 day simple moving average is $115.11 and its 200-day simple moving average is $113.46.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.90 EPS. Sell-side analysts forecast that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BNTX. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. JPMorgan Chase & Co. decreased their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target for the company. BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, Morgan Stanley decreased their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $143.73.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.